Business News | JFL Life Sciences Limited SME IPO - NSE Emerge Opens on 25th August 2022; Intends to Raise Rs 1,816.58 Lakhs Through 29,78,000 Equity Shares
Get latest articles and stories on Business at LatestLY. JFL Life Sciences Limited, engaged in the business of manufacturing pharmaceutical products having experience of more than a decade, is all set to raise Rs 1,816.58 Lakhs through an initial public offering (IPO). The issue opens on the 25th of August and will be listed on NSE Emerge.
New Delhi [India], August 25 (ANI/PNN): JFL Life Sciences Limited, engaged in the business of manufacturing pharmaceutical products having experience of more than a decade, is all set to raise Rs 1,816.58 Lakhs through an initial public offering (IPO). The issue opens on the 25th of August and will be listed on NSE Emerge.
The public issue of JFL Life Sciences Limited is of 29,78,000 equity shares of Face Value Rs 10 each ("EQUITY SHARES") for cash at a price of Rs 61/- per equity share (including a securities premium of Rs 51/- per equity share) (the issue price) aggregating Rs 1,816.58 LACS of the issue. 1,50,000 equity shares aggregating to Rs 91.50 Lakhs will be reserved for market maker ("Market Maker Reservation Portion"). The issue, less the Market Maker Reservation Portion, i.e., issue of 28,28,000 equity shares of Face Value of Rs 10/- EACH at an issue price of Rs 61/- per equity share, aggregating to Rs 1,725.08 Lakhs, which is hereinafter referred to as "The Net Issue". The issue and the Net Issue will constitute 27.08 per cent and 25.71 per cent, respectively of the post issue paid up equity share capital of the company. The company will list at NSE Emerge. The Lead manager of the issue is GYR Capital Advisors Pvt Ltd and the Registrar to the issue is KFin Technologies Ltd. The issue opens on August 25 and will close on August 30, 2022 and will subsequently be listed on NSE Emerge.
Also Read | Moto G72 India Launch Timeline Tipped, Likely To Feature Triple Rear Cameras.
The company intends to utilize the proceeds of the Issue to meet the following objectives:
1. Repayment of secured and unsecured loans
2. Funding the working capital requirements of the company
3. General Corporate Purposes
JFL Life Sciences Limited is engaged in the business of manufacturing pharmaceutical products. Their product portfolio consists of Dry powder injections (B-Lactam), Tablets and Capsules (B-Lactam) solid oral dosage form and Tablet and capsules (general) Solid Oral Dosage Form and Oral rehydration solutions (ORS). With market presence in pan India, products of JFL supplies to 10 developed and developing countries throughout the World. To maintain its competitiveness and to further the cause of health care JFL has laid a strong R&D foundation and an FDA approved state of the art manufacturing facility near Ahmedabad.
The Company has registered their products to manufacture in various countries like sovereign of Kenya, Nigeria, Yemen and Myanmar. Few of their products are also registered with Ukraine, Uzbekistan, and Kazakhstan as well. This also makes them a 'one-stop-shop' service provider for catering to all of the customer's needs domestically as well as internationally.
The promoters, Smiral Ashwinbhai Patel and Tejal Smiralbhai Patel are actively involved in the day-to-day business of the company and are the guiding force behind the strategic decisions for the Company. Their management team and other key management personnel are well qualified and have extensive industry expertise, and have been responsible for the operational growth.
This Story has been provided by PNN. ANI will not be responsible in any way for the content in this article. (ANI/PNN)
(This is an unedited and auto-generated story from Syndicated News feed, LatestLY Staff may not have modified or edited the content body)